Page last updated: 2024-10-16

carbamates and HIV

carbamates has been researched along with HIV in 40 studies

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen."9.19Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014)
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification."9.19Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014)
"Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum."9.17Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. ( Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE, 2013)
"The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily."7.75Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009)
"To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir."7.72HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. ( Chou, S; Marousek, GI; Murphy, MD, 2004)
"STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen."5.19Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014)
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification."5.19Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014)
"Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum."5.17Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. ( Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE, 2013)
"To evaluate the pharmacokinetic compatibility of a ritonavir-boosted indinavir-fosamprenavir combination among patients with human immunodeficiency virus (HIV)."5.13Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. ( Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008)
"Darunavir is the result of wide and in-depth investigation into HIV protease inhibitors (PIs)."4.84[Chemical characteristics, mechanism of action and antiviral activity of darunavir]. ( Hidalgo Tenorio, C; Pasquau Liaño, J, 2008)
"The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV)."4.02Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus. ( Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K, 2021)
"Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials."3.76Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. ( Briz, V; de José, MI; de Ory, SJ; González-Tomé, MI; León Leal, JA; Mellado, MJ; Moreno, D; Muñoz-Fernández, MA; Palladino, C; Policarpo, SN; Ramos, JT; Silveira, LF, 2010)
"The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily."3.75Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009)
"To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir."3.72HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. ( Chou, S; Marousek, GI; Murphy, MD, 2004)
"Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI-experienced HIV-infected patients."3.72Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. ( Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M, 2004)
"The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection."3.71Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. ( Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL, 2002)
" We initially introduced new structural templates, particulary nonpeptidic conformationally constrained P 2 ligands that would efficiently mimic peptide binding in the S 2 subsite of the protease and provide enhanced bioavailability to the inhibitor."2.44Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. ( Chapsal, BD; Ghosh, AK; Mitsuya, H; Weber, IT, 2008)
"Mollecarbamates 1-4 are a family of compounds that possess repeating o-carboxyphenethylamide units and a carbamate moiety, while the molleureas 5-8 contain tetra- and penta-repeating carboxyphenethylamide units and a urea bridge in different positions."1.46Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. ( Aknin, M; Barrows, LR; Carmeli, S; Gauvin-Bialecki, A; Issac, M; Kashman, Y; Pond, CD, 2017)

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (7.50)18.2507
2000's23 (57.50)29.6817
2010's13 (32.50)24.3611
2020's1 (2.50)2.80

Authors

AuthorsStudies
Dehghan Manshadi, SA1
Merat, S1
Mohraz, M1
Rasoolinejad, M1
Sali, S1
Mardani, M1
Tabarsi, P1
Somi, MH1
Sedghi, R1
Tayeri, K1
Nikbin, M1
Karimi, J1
Sharifi, AH1
Kalantari, S1
Norouzi, A1
Merat, D1
Malekzadeh, Z1
Mirminachi, B1
Poustchi, H1
Malekzadeh, R1
Issac, M1
Aknin, M1
Gauvin-Bialecki, A1
Pond, CD1
Barrows, LR1
Kashman, Y1
Carmeli, S1
Smolders, EJ1
Smit, C1
T M M de Kanter, C1
Dofferiiof, ASM1
Arends, JE1
Brinkman, K1
Rijnders, B1
van der Valk, M1
Reiss, P1
Burger, DM1
Yoshimura, Y1
Miyata, N1
Komatsu, H1
Tachikawa, N1
Sulkowski, MS1
Wu, J1
Huang, P1
Fan, H1
Tian, T1
Xia, X1
Fu, Z1
Wang, Y1
Ye, X1
Yue, M1
Zhang, Y1
Fulco, PP1
Ayala-Sims, VA1
Schrijvers, R1
Debyser, Z1
Arribas, JR1
Pialoux, G1
Gathe, J1
Di Perri, G1
Reynes, J1
Tebas, P1
Nguyen, T2
Ebrahimi, R1
White, K2
Piontkowsky, D2
Pozniak, A1
Markowitz, M1
Mills, A1
Stellbrink, HJ1
Antela, A1
Domingo, P1
Girard, PM1
Henry, K1
Garner, W1
Guyer, B1
Gatti, F1
Nasta, P1
Loregian, A1
Puoti, M1
Matti, A1
Pagni, S1
de Requena, DG1
Prestini, K1
Parisi, SG1
Bonora, S1
Palù, G1
Carosi, G1
Pasquau Liaño, J1
Hidalgo Tenorio, C1
Palladino, C1
Briz, V1
Policarpo, SN1
Silveira, LF1
de José, MI1
González-Tomé, MI1
Moreno, D1
León Leal, JA1
Mellado, MJ1
de Ory, SJ1
Ramos, JT1
Muñoz-Fernández, MA1
Breeze, S1
Cespedes, MS1
Castor, D1
Ford, SL1
Lee, D1
Lou, Y2
Pakes, GE1
Aberg, JA1
Bogner, JR1
Eberle, J1
Troendle, U1
Goebel, FD1
Schnell, T1
Schmidt, B1
Moschik, G1
Thein, C1
Paatz, C1
Korn, K1
Walter, H1
Bates, M1
Wrin, T1
Huang, W1
Petropoulos, C1
Hellmann, N1
Murphy, MD1
Marousek, GI1
Chou, S1
Hasson, H1
Gianotti, N1
Danise, A1
Seminari, E2
Boeri, E1
Nozza, S1
Castagna, A1
Lazzarin, A1
Randolph, JT1
DeGoey, DA1
Marcelin, AG1
Affolabi, D1
Lamotte, C2
Mohand, HA1
Delaugerre, C1
Wirden, M1
Voujon, D1
Bossi, P1
Ktorza, N1
Bricaire, F1
Costagliola, D1
Katlama, C1
Peytavin, G2
Calvez, V1
Taourirte, M1
Lazrek, HB1
Rochdi, A1
Vasseur, JJ1
Engels, JW1
DeJesus, E1
Piliero, PJ1
Summers, K1
Wire, MB1
Stein, DS1
Masterman, A1
Min, SS1
Shelton, MJ1
Ghosh, AK1
Chapsal, BD1
Weber, IT1
Mitsuya, H1
Spagnuolo, V1
Gentilini, G1
De Bona, A1
Galli, L1
Uberti-Foppa, C1
Soldarini, A1
Dorigatti, F1
Picchio, G1
De Meyer, S1
de Béthune, MP1
Ofotokun, I1
Acosta, EP1
Lennox, JL1
Pan, Y1
Easley, KA1
Bilello, JA1
Drusano, GL1
Levin, J1
Chang, HE1
Clotet, B1
Martínez-Picado, J1
Arrizabalaga, J1
Ruiz, L1
Duval, X1
Race, E1
Descamps, D1
Damond, F1
Clavel, F1
Leport, C1
Vilde, JL1
Solignac, M1
Gallego, O1
Corral, A1
de Mendoza, C1
Soriano, V1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus[NCT03369327]Phase 3232 participants (Actual)Interventional2017-01-01Completed
A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir D[NCT01475838]Phase 3438 participants (Actual)Interventional2011-11-30Completed
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients[NCT03789968]411 participants (Actual)Observational2019-09-01Completed
A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Diso[NCT01495702]Phase 3439 participants (Actual)Interventional2011-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01475838)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
Stribild40
PI+RTV+FTC/TDF32

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01475838)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
Stribild61
PI+RTV+FTC/TDF71

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 48

Interventionpercentage of participants (Number)
Stribild93.8
PI+RTV+FTC/TDF87.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 96

Interventionpercentage of participants (Number)
Stribild86.9
PI+RTV+FTC/TDF69.8

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01495702)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
Stribild56
NNRTI+FTC/TDF58

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01495702)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
Stribild83
NNRTI+FTC/TDF101

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 48

Interventionpercentage of participants (Number)
Stribild93.4
NNRTI+FTC/TDF88.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 96

Interventionpercentage of participants (Number)
Stribild86.6
NNRTI+FTC/TDF80.4

Reviews

6 reviews available for carbamates and HIV

ArticleYear
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 10

    Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug

2008
Practical applications of viral fitness in clinical practice.
    Current opinion in infectious diseases, 2003, Volume: 16, Issue:1

    Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests

2003
Peptidomimetic inhibitors of HIV protease.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV;

2004
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Accounts of chemical research, 2008, Volume: 41, Issue:1

    Topics: Carbamates; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV; HIV Protease; HIV Protease

2008
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
    AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1

    Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors;

2008
[Resistance to protease inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:Monografic

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhi

2001

Trials

6 trials available for carbamates and HIV

ArticleYear
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E

2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E

2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E

2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E

2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV;

2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV;

2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV;

2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV;

2014
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adult; Area Under Curve; Carbamates; Disease Transmission, Infectious; Female; Fetal Blood; Furans;

2013
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
    European journal of medical research, 2003, Feb-21, Volume: 8, Issue:2

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination

2003
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot

2006
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Pharmacotherapy, 2008, Volume: 28, Issue:1

    Topics: Adult; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Dose-Response Relationshi

2008

Other Studies

28 other studies available for carbamates and HIV

ArticleYear
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
    International journal of clinical practice, 2021, Volume: 75, Issue:8

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic

2021
Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar.
    Journal of natural products, 2017, 06-23, Volume: 80, Issue:6

    Topics: Animals; Carbamates; HIV; Humans; Isoquinolines; Madagascar; Microbial Sensitivity Tests; Molecular

2017
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
    Journal of acquired immune deficiency syndromes (1999), 2017, 10-01, Volume: 76, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carba

2017
Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
    AIDS (London, England), 2018, 01-02, Volume: 32, Issue:1

    Topics: Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Hepacivirus; Hepatitis C,

2018
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV I

2019
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
    Virology journal, 2019, 01-17, Volume: 16, Issue:1

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Coinfectio

2019
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, May-15, Volume: 71, Issue:10

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtric

2014
Switching STRATEGIES in HIV treatment.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:7

    Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Inf

2014
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:3

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Elas

2009
Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count

2010
A 4-drug combination (Stribild) for HIV.
    The Medical letter on drugs and therapeutics, 2012, Nov-26, Volume: 54, Issue:1404

    Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Bl

2012
Novel HIV-1 treatment Stribild™ gains regulatory approval.
    Expert review of clinical pharmacology, 2012, Volume: 5, Issue:6

    Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir,

2012
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibito

2003
Viral patterns of unboosted 908 identified.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial

2003
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 30, Issue:1

    Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furan

2004
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therap

2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Femal

2004
Homo and heterodimers of ddI, d4T and AZT: influence of (5'-5') thiolcabonate-carbamate linkage on anti-HIV activity.
    Nucleosides, nucleotides & nucleic acids, 2005, Volume: 24, Issue:5-7

    Topics: Anti-HIV Agents; Antiviral Agents; Carbamates; Didanosine; Dimerization; HIV; HIV Infections; Models

2005
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
    The new microbiologica, 2007, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepa

2007
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
    The Journal of infectious diseases, 1996, Volume: 173, Issue:6

    Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections;

1996
[Second chance therapy. New protease inhibitor for salvage therapy].
    MMW Fortschritte der Medizin, 2000, Mar-13, Volume: 142 Suppl 1

    Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans;

2000
New protease drug shows early promise.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995

    Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Drug Resistance, Microbial; Drug Sy

1995
Conference looks at HIV drug resistance.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9

    Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Inf

1995
[Determining resistance in HIV therapy. Careful interpretation only].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infect

2001
Amprenavir (Agenerase).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans

2000
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furan

2002
[Advances in the domain of HIV].
    Presse medicale (Paris, France : 1983), 2002, Jan-19, Volume: 31, Issue:2

    Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combi

2002
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, May-01, Volume: 34, Issue:9

    Topics: Amino Acid Substitution; Anti-HIV Agents; Asparagine; Carbamates; Drug Hypersensitivity; Furans; Gen

2002